1. Scrip
  2. >>R&D
  3. >>Clinical Trials

TG Therapeutics Raises $60m Following Combo Therapy Success In CLL

 
• By Joseph Haas

One day after reporting that its umbralisib/ublituximab combo met a PFS endpoint in CLL, TG raises $60m as it prepares for a year-end filing of the combo. Umbralisib monotherapy is under FDA review already.

Winning, victory, success and surviving concept. Green board game pawn stand alone, the white rest fallen. Eliminating competitors. One against the others. Last man standing. Against all odds.
TG Therapeutics' U2 combo topped a comparator regimen for PFS in CLL patients

A bet TG Therapeutics Inc. placed in 2018 appears to be paying off now as the firm reported positive top-line progression-free survival data for its umbralisib/ublituximab combination regimen in chronic lymphocytic leukemia on 5 May, and then raised $60m on the strength of those data on 6 May. TG hopes to file the combo for US approval in first-line and relapsed/refractory CLL before the end of 2020.

The New York-based biotech initially planned to file the combo regimen with the US Food and Drug Administration in 2018 based on an interim analysis looking at the objective response rate, but the data were not mature at that time

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

 
• By Sushmita Panda

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

More from R&D

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.